Small cohorts are the deliberate design choice behind Medrio’s Early Adopter Program, an invitation-only arrangement that gives sponsors and CROs a direct hand in shaping CTMS, eTMF, Site Payments, and next-generation EDC before any of those products reach general availability. The commercial terms make the offer concrete: Level 2 participants run their first study free, with 90 percent off additional studies, and Level 3 members lock in permanently discounted pricing, and the source indicates all early adopters keep their protected pricing after the product reaches general release.
The structure runs three levels, each tied to a different point in the development cycle. Level 1 is no-cost access to concepts and prototypes, with the chance to validate requirements before any live build exists. Level 2 moves into pressure-testing early product versions against actual workflows, with structured feedback sessions that include Medrio’s product and executive leaders. Level 3 is production use ahead of broad availability, with first access to new capabilities as they ship. The progression means a team can enter wherever its study timing and readiness fit, rather than waiting for a finished product to evaluate.
The underlying problem the program addresses is fragmented clinical trial technology, a condition that hits smaller and scaling organizations hardest because they carry fewer internal resources to bridge gaps between systems. Founded more than 20 years ago,, Medrio built its reputation on electronic data capture for teams that found enterprise EDC platforms oversized for their needs. The Early Adopter Program extends that positioning: rather than shipping a finished CTMS or eTMF and asking customers to adapt, Medrio is folding customer workflows into the build itself, with the discount structure as the exchange for that input.
Participation is not automatic. Medrio evaluates product fit, study timing, use case, customer readiness, and what kind of validation each cohort requires,, which keeps cohort size small enough that every member works directly with the product team. The practical marker to watch is whether teams currently running disconnected CTMS and EDC systems, managing site payments manually, or maintaining eTMFs in standalone tools decide that discounted early access is worth committing to structured feedback cycles. The program’s value to Medrio depends entirely on that tradeoff being attractive enough to draw the teams whose real-world complexity will actually test the products.
Source link: https://medrio.com/blog/early-adopter-program/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
